Workflow
Yatai pharm(002370)
icon
Search documents
亚太药业(002370) - 2019 Q4 - 年度财报
2020-03-13 16:00
Financial Performance - The company reported a significant increase in revenue for 2019, with total revenue reaching RMB 1.2 billion, representing a year-on-year growth of 15%[13]. - The net profit attributable to shareholders was RMB 200 million, an increase of 10% compared to the previous year[13]. - The company's operating revenue for 2019 was ¥709,291,124.12, a decrease of 45.84% compared to ¥1,309,709,237.78 in 2018[6]. - The net profit attributable to shareholders was -¥2,068,654,854.33, representing a decline of 1,095.57% from ¥207,785,781.83 in the previous year[6]. - The company reported a gross margin of 45%, maintaining a stable margin compared to the previous year[13]. - The operating profit was -¥2,068,404,058.83, representing a decline of 956.84% year-over-year[49]. - The company reported a total revenue of ¥709,291,124.12, a decrease of 45.84% compared to the previous year[49]. - The company reported a basic earnings per share of -¥3.86, a decline of 1,089.74% from ¥0.39 in 2018[6]. Investment and Development - The company plans to invest in new product development, focusing on innovative drugs and generics, aiming to launch at least 5 new products in the next fiscal year[13]. - The company is committed to improving its R&D capabilities, with a budget increase of 25% for research and development activities in 2020[13]. - The company is actively developing high-end generic drugs and innovative drugs, enhancing its R&D capabilities and product pipeline[40]. - The company focused on R&D, adding 4 new invention patents and having 9 patent applications accepted during the reporting period[49]. - The company is conducting consistency evaluations for 11 products, with 3 products having completed clinical equivalence studies and are about to apply for production[49]. Market Expansion and Strategy - The company has outlined an expansion strategy targeting international markets, with plans to enter at least 3 new countries by the end of 2020[13]. - User data indicates a growing customer base, with a 20% increase in active users over the past year, reaching 1 million active users[13]. - The company has established a sales network covering hospitals, pharmacies, and other commercial channels, transitioning from traditional marketing to precision marketing to enhance sales efficiency[31]. - The company aims to enhance its market share by strengthening its marketing network and optimizing product structure in 2020[108]. Financial Management and Risks - The company will not distribute cash dividends or issue bonus shares for the fiscal year 2019, opting to reinvest profits into business growth[5]. - The company is facing potential risks including regulatory changes and rising production costs, which could impact future profitability[4]. - The company is focused on risk management and improving internal control systems to mitigate operational risks[108]. - The company faces risks related to industry regulations and potential price declines in drug bidding processes due to national healthcare cost control measures[111]. - The company is aware of inherent risks in drug production, including potential product recalls and regulatory penalties due to quality issues[112]. Regulatory and Compliance Issues - The company is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws[117]. - The company is currently in the process of addressing the implications of the ongoing investigations and audit findings[138]. - The company has implemented new accounting standards effective from January 1, 2019, which include changes in the classification and measurement of financial assets[144]. - The company received investigation notices from the China Securities Regulatory Commission due to suspected violations of information disclosure laws, which are still under investigation as of the audit report date[138]. Asset Management and Acquisitions - The company has completed a major asset acquisition, purchasing 100% of Shanghai New Peak Biopharmaceuticals, enhancing its product portfolio[10]. - The company recognized an investment loss of 1.24 billion yuan due to the loss of control over Shanghai New Peak and its subsidiaries, leading to significant operational losses in 2019[48]. - The company has committed to invest a total of ¥90,000,000 in the acquisition of Shanghai New Peak Biopharmaceuticals, with a cumulative investment of ¥88,875,000, achieving 98.75% of the planned investment progress[97]. Environmental and Quality Control - The company has established a comprehensive quality control system from raw material procurement to product sales, adhering to GMP standards[112]. - The company has invested in environmental protection and has passed ISO14001 certification, demonstrating its commitment to environmental management[178]. - The company has established a wastewater treatment facility with a design capacity of 365 tons per day, which has been operating normally during the reporting period[179]. Shareholder and Governance Matters - The company has a clear and compliant cash dividend policy, ensuring the protection of minority shareholders' rights[123]. - The company has established a comprehensive corporate governance structure and internal control system to protect the rights of shareholders and creditors[174]. - The company has committed to not transferring or entrusting the management of its shares for a period of 36 months following its stock listing[135].
亚太药业(002370) - 2019 Q3 - 季度财报
2019-10-29 16:00
Financial Performance - Operating revenue decreased by 49.10% to CNY 150,885,573.26 for the current period compared to the same period last year[7]. - Net profit attributable to shareholders was CNY -33,330,515.92, a decline of 194.63% year-on-year[7]. - Basic earnings per share were CNY -0.06, down 185.71% from the previous year[7]. - Net profit decreased by 95.89% year-on-year, mainly due to a reduction in operating income[16]. - Operating cash flow net amount decreased by 640.47% year-on-year, primarily due to a decrease in cash received from sales of goods and services[16]. - The total operating revenue for Q3 2019 was CNY 150,885,573.26, a decrease of 49% compared to CNY 296,458,738.80 in the same period last year[46]. - Net profit for Q3 2019 was a loss of CNY 33,389,014.26, compared to a profit of CNY 35,314,260.83 in Q3 2018[47]. - The company's operating profit decreased to CNY 4,581,023.25 from CNY 20,812,748.72, marking a decline of approximately 78%[50]. - The total comprehensive income for the period was CNY -33,389,014.26, contrasting with CNY 35,462,265.89 in the previous year[50]. - The net profit for Q3 2019 was CNY 3,404,699.91, a significant decrease of 81.9% compared to CNY 18,766,404.09 in Q3 2018[50][52]. Assets and Liabilities - Total assets increased by 34.16% to CNY 4,423,602,030.98 compared to the end of the previous year[7]. - The company's total assets as of September 30, 2019, amounted to CNY 3,225,456,545.08, an increase from CNY 2,265,925,534.69 at the end of 2018[44]. - The total liabilities reached CNY 1,714,528,136.28, compared to CNY 773,072,849.17 at the end of 2018[38]. - The company's long-term borrowings increased to CNY 270,000,000.00 from CNY 164,600,000.00[38]. - The total liabilities amounted to CNY 773,072,849.17, with total equity at CNY 2,524,154,329.98, resulting in total assets of CNY 3,297,227,179.15[73]. - The company's current assets totaled CNY 1,110,522,958.58, significantly up from CNY 490,054,412.75 year-on-year[42]. - The total owner's equity attributable to shareholders was CNY 2,512,310,609.62, with retained earnings of CNY 606,951,794.75[73]. Cash Flow - Net cash flow from operating activities was CNY -10,063,166.52, representing a 64.99% decrease compared to the same period last year[7]. - Cash and cash equivalents increased by 137.47% compared to the end of the previous year, mainly due to the proceeds from the public issuance of convertible bonds[15]. - Cash flow from operating activities showed a net outflow of CNY 40,823,667.36, compared to a net inflow of CNY 7,553,432.27 in the previous period[63]. - Cash flow from investing activities showed a net outflow of CNY 312,974,308.76, compared to a net inflow of CNY 80,262,704.83 in the previous period, indicating increased investment expenditures[68]. - Cash flow from financing activities resulted in a net inflow of CNY 925,763,484.76, a recovery from a net outflow of CNY 53,649,445.60 in the previous period[68]. Shareholder Information - The total number of shareholders at the end of the reporting period was 36,862[11]. - Zhejiang Apac Group Co., Ltd. held 20.15% of the shares, making it the largest shareholder[11]. - Shareholders plan to reduce their holdings by up to 1.6 million shares through various methods, with no reductions made as of the report date[19]. Government Subsidies and Other Income - The company received government subsidies amounting to CNY 17,076,989.68 during the reporting period[8]. - Other income increased by 166.65% year-on-year, mainly due to an increase in government subsidies received[16]. Management and Compliance - The company discovered a violation of external guarantees by its subsidiary, which was not approved through normal procedures[18]. - The company has made commitments regarding shareholding and management practices to ensure compliance and protect shareholder interests[23]. - The company has committed to not engage in similar business activities as Zhejiang Apac Pharmaceutical Co., Ltd. for a period of 36 months following its stock listing[22]. Financial Expenses - Financial expenses increased by 233.45% year-on-year, mainly due to increased interest expenses on bank loans and accrued interest on convertible bonds[16]. - The company reported a financial expense of CNY 31,052,117.89 for the year-to-date, significantly higher than CNY 9,312,450.02 in the same period last year[53]. Research and Development - Research and development expenses for Q3 2019 were CNY 11,701,558.12, down from CNY 16,671,349.31 in the previous year[46]. - Research and development expenses decreased to CNY 21,223,667.43, down 26.8% from CNY 28,963,613.22 in the previous period[59].
亚太药业(002370) - 2019 Q2 - 季度财报
2019-08-30 16:00
Financial Performance - Zhejiang Yatai Pharmaceutical reported a revenue of RMB 1.2 billion for the first half of 2019, representing a year-on-year increase of 15%[12]. - The company's net profit attributable to shareholders reached RMB 200 million, up 10% compared to the same period last year[12]. - The company's operating revenue for the reporting period was ¥574,198,421.64, a decrease of 13.30% compared to the same period last year[16]. - The net profit attributable to shareholders was ¥40,239,090.25, down 69.36% year-on-year[16]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥31,539,814.08, a decline of 75.68% compared to the previous year[16]. - The gross margin for the first half of 2019 was reported at 45%, slightly down from 47% in the previous year due to rising production costs[12]. - Future guidance estimates a revenue growth of 18% for the full year 2019, driven by new product launches and market penetration[12]. - The company achieved operating revenue of CNY 574,198,421.64, a decrease of 13.30% compared to the same period last year[39]. - Operating profit was CNY 53,817,469.92, down 66.24% year-on-year, while net profit attributable to shareholders decreased by 69.36% to CNY 40,239,090.25[39]. - The company reported a profit before tax of CNY 53.82 million, down from CNY 159.44 million in the first half of 2018[179]. - The total comprehensive income for the first half of 2019 was CNY 28,202,893.61, compared to CNY 66,231,677.34 in the same period of 2018, indicating a significant decline[185]. Research and Development - The company plans to invest RMB 300 million in R&D for new drug development in the next fiscal year, focusing on innovative therapies[12]. - The company is focusing on enhancing R&D capabilities, particularly in high-end generics, innovative drugs, and biopharmaceuticals, while also expanding its marketing network[39][40]. - Research and development expenses rose to CNY 22.39 million, an increase of 34.56% compared to CNY 16.65 million in the previous year[178]. - The company is increasing R&D investments to enhance product innovation and maintain competitive advantage in the pharmaceutical sector[83]. Market Expansion and Strategy - Market expansion efforts include entering two new provinces, aiming for a 25% increase in market share by the end of 2020[12]. - The company has initiated a strategic acquisition of a biotech firm for RMB 500 million to enhance its product pipeline[12]. - The sales model has shifted towards professional academic marketing and precision marketing to enhance sales efficiency and market share[29]. - The company is implementing marketing strategy adjustments to optimize channel structure and increase market penetration[40]. Financial Position and Assets - The total assets at the end of the reporting period were ¥4,459,540,936.27, an increase of 35.25% compared to the end of the previous year[16]. - The net assets attributable to shareholders at the end of the reporting period were ¥2,730,554,708.42, up 8.69% from the previous year[16]. - Cash and cash equivalents increased by 149.33% compared to the beginning of the period, primarily due to the issuance of convertible bonds[32]. - The company’s total assets included cash and cash equivalents, which accounted for 29.88% of total assets, up from 25.49% in the previous year[51]. - The company's total assets reached CNY 3.23 billion, up from CNY 2.27 billion at the end of the previous year[176]. Regulatory and Operational Risks - The company is facing regulatory risks related to drug pricing and quality control, which could impact future earnings[4]. - The pharmaceutical industry is highly regulated, and changes in policies may increase operational costs and negatively impact financial performance[78]. - The implementation of volume-based procurement policies may lead to significant reforms in drug bidding and pricing, compressing profit margins for the company[80]. - The company has established a quality control system in compliance with GMP standards, but risks related to product quality still exist, which could adversely affect operations and reputation[80]. - The company faces risks related to new drug development, including long cycles and high costs, which may lead to delays or failures in product launches[82]. Cash Flow and Financing - The net cash flow from operating activities was -¥30,760,500.84, representing a decrease of 184.74% year-on-year[16]. - Cash flow from operating activities generated a net outflow of CNY 30,760,500.84, a decrease from a net inflow of CNY 36,297,831.71 in the first half of 2018[188]. - Cash flow from financing activities generated a net inflow of CNY 1,098,698,823.54, significantly higher than CNY 330,076,662.30 in the first half of 2018[189]. - The company issued bonds, receiving CNY 955,000,000.00, which contributed to the increase in cash flow from financing activities[189]. Shareholder and Corporate Governance - The company will not distribute cash dividends for this fiscal year, opting to reinvest profits into business growth[4]. - The company has not declared any cash dividends or stock bonuses for the half-year period, indicating a focus on reinvestment[89]. - The controlling shareholder, Zhejiang Yatai Group Co., Ltd., committed to not engage in any similar business activities that compete with Zhejiang Yatai Pharmaceutical and its subsidiaries[93]. - The management team has committed to not engage in similar business activities for two years after leaving the company[93]. Environmental Compliance - The company has a wastewater treatment facility with a design capacity of 365 tons per day, which has been operating normally during the reporting period[123]. - The company’s wastewater discharge meets the Class III standards of the "Comprehensive Discharge Standard for Wastewater" (GB8978-1996)[123]. - The company has established an emergency response plan for environmental incidents and has implemented daily inspections to ensure effective measures are in place[126]. Miscellaneous - The company did not conduct an audit for the semi-annual financial report[96]. - There were no significant litigation or arbitration matters during the reporting period[99]. - The company has not reported any new product launches or technological advancements during this period[197].
亚太药业(002370) - 2019 Q1 - 季度财报
2019-04-26 16:00
浙江亚太药业股份有限公司 2019 年第一季度报告全文 浙江亚太药业股份有限公司 2019 年第一季度报告 2019 年 04 月 1 浙江亚太药业股份有限公司 2019 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人陈尧根、主管会计工作负责人何珍及会计机构负责人(会计主管 人员)何珍声明:保证季度报告中财务报表的真实、准确、完整。 2 浙江亚太药业股份有限公司 2019 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入(元) | 366,129,207.79 | 319,164,772.95 | 14.71% | | 归属于上市公司股东的净利润(元) | 56,792,536.07 | 65,492,88 ...
亚太药业(002370) - 2018 Q4 - 年度财报
2019-04-26 16:00
Financial Performance - The company's operating revenue for 2018 was CNY 1,309,709,237, representing a 20.94% increase compared to CNY 1,082,951,050 in 2017[17]. - The net profit attributable to shareholders for 2018 was CNY 207,785,781.83, a 2.79% increase from CNY 202,152,119.51 in 2017[17]. - The net cash flow from operating activities decreased by 71.08% to CNY 36,994,829.22 from CNY 127,593,606.87 in 2017[17]. - The total assets at the end of 2018 were CNY 3,297,227,179, reflecting a 20.42% increase from CNY 2,738,063,462 at the end of 2017[18]. - The net assets attributable to shareholders increased by 6.50% to CNY 2,512,310,609 from CNY 2,359,015,565 in 2017[18]. - The basic earnings per share for 2018 was CNY 0.39, up 2.63% from CNY 0.38 in 2017[17]. - The diluted earnings per share for 2018 was also CNY 0.39, consistent with the basic earnings per share[17]. - The weighted average return on equity for 2018 was 8.55%, down from 8.91% in 2017[17]. - The company reported a quarterly operating revenue of CNY 351,001,133.37 in Q4 2018, with a net profit of CNY 41,214,792.51[22]. - The company reported a total revenue of 9,000,103.14 in the current period, an increase from 8,610,889.04 in the previous period, reflecting a growth of approximately 4.5%[24]. Dividend Policy - The company plans to distribute a cash dividend of 0.50 CNY per 10 shares to all shareholders, based on a total of 536,494,456 shares[4]. - The proposed cash dividend for 2018 was RMB 0.50 per 10 shares, totaling RMB 26,824,722.80, with no stock dividends or capital reserve conversions planned[126]. - The company's net profit for 2018 was RMB 105,838,107.48, with a distribution plan that allocated 25.3% of the profit to cash dividends[126]. - The cash dividend for 2018 represented 12.91% of the net profit attributable to shareholders[124]. - The company has maintained a consistent cash dividend policy over the past three years, with no stock dividends issued during this period[125]. Research and Development - The company has a focus on new drug research and development, with a commitment to clinical trials and regulatory compliance[9]. - The company is investing in innovative drug development, aiming to introduce new products that meet clinical needs[9]. - The company has established 15 innovative drug projects currently in preclinical research, clinical application, or preparing for NDA submission[50]. - In 2018, the company's R&D expenditure reached ¥150,333,541.34, accounting for 11.48% of total revenue, a significant increase of 209.64% compared to 2017[72]. - The company is actively pursuing the development of high-end generic drugs and innovative drugs, responding to national policies encouraging new drug creation[73]. Market Expansion and Strategy - The company is actively pursuing market expansion strategies, including potential mergers and acquisitions to enhance its product portfolio[9]. - The company has outlined future growth strategies that include enhancing its research capabilities and expanding its market reach[9]. - The company is focusing on internal expansion and external acquisitions to optimize its industry layout and seek new growth points[54]. - The company aims to build a health industry ecosystem through strategic investments and partnerships[54]. - The company is focused on mergers and acquisitions within the pharmaceutical industry to transition into high value-added sectors[105]. Risk Management - The company emphasizes the importance of risk factors including industry regulation changes, drug bidding and price declines, and production cost increases[4]. - The company acknowledges the potential impact of talent retention challenges on its operational performance[4]. - The company faces risks from industry regulations and policy changes that could impact operational costs and performance[110]. - The company is exposed to risks related to drug bidding and price declines due to healthcare cost control measures[110]. - The company is aware of the risks associated with long-cycle contracts in R&D services, which may lead to delays or adjustments affecting revenue[117]. Operational Efficiency - The company is exploring new technologies to improve operational efficiency and reduce costs[9]. - The company has optimized its product structure, increasing the revenue share of high-margin products, contributing to overall revenue growth[32]. - The company is taking measures to control costs and improve efficiency through technological and management innovations[116]. - The company is enhancing its internal control and external management to mitigate risks associated with the increasing number of subsidiaries and their operational challenges[113]. Compliance and Governance - The company has established a comprehensive corporate governance structure and internal control system to protect the rights of shareholders and creditors, ensuring fair and transparent information disclosure[169]. - The company has implemented strict measures to ensure that its controlling shareholders do not engage in similar business activities, thereby protecting its market interests[131]. - The company has established strict compliance measures to avoid any conflicts of interest with Shanghai New Peak Biopharmaceutical Co., Ltd.[130]. - The company confirmed that there were no non-operating fund occupations by controlling shareholders or related parties[137]. - The audit firm, Tianjian Accounting Firm, has been engaged for 11 consecutive years, with the audit fee for the current period set at 800,000 yuan[144]. Environmental Responsibility - The company has actively engaged in environmental protection efforts, achieving ISO14001 certification and implementing clean production processes to reduce costs and environmental impact[171]. - The company has constructed and operates pollution control facilities that are compliant with environmental regulations, ensuring stable operation[175]. - The company has established emergency response plans for environmental incidents to mitigate potential impacts on the surrounding environment[178]. - The company’s noise emissions comply with the GB12348-2008 standard, ensuring minimal disturbance to the surrounding area[176]. Shareholder Structure - The total number of shares is 536,494,456, with 128,494,456 shares (23.95%) under limited sale conditions and 408,000,000 shares (76.05%) under unrestricted sale conditions[186]. - The largest shareholder, Zhejiang Apac Pharmaceutical Group Co., Ltd., holds 108,100,000 shares, representing 20.15% of total shares, with a decrease of 35,500,000 shares during the reporting period[188]. - The company has a total of 7,031 common shareholders at the end of the reporting period, compared to 13,554 at the previous month-end[188]. - The actual controller of the company is Mr. Chen Yaogen, with Zhejiang Apac Group as the controlling shareholder[189]. - The report indicates no changes in the company's asset and liability structure during the reporting period[187].
亚太药业(002370) - 2018 Q3 - 季度财报
2018-10-28 16:00
Financial Performance - Operating revenue decreased by 10.12% to CNY 296,458,738.80 compared to the same period last year, but increased by 16.28% year-to-date[7] - Net profit attributable to shareholders decreased by 28.03% to CNY 35,221,089.13 compared to the same period last year, while year-to-date net profit increased by 10.64% to CNY 166,570,989.32[7] - Basic earnings per share decreased by 22.22% to CNY 0.07 for the current period[7] - The weighted average return on net assets was 1.44%, a decrease of 0.70% compared to the same period last year[7] - The company reported non-recurring gains and losses totaling CNY 5,388,730.44 for the year-to-date[8] - The net profit attributable to shareholders for 2018 is expected to be between 20,215.21 and 24,258.25 million yuan, representing a growth range of 0.00% to 20.00% compared to 2017[26] - The company has maintained steady growth in its operating performance[26] Assets and Liabilities - Total assets increased by 18.38% to CNY 3,241,266,063.97 compared to the end of the previous year[7] - Prepayments increased by 161.17% compared to the beginning of the period, mainly due to the increase in technical service fees paid by subsidiaries[15] - Inventory increased by 35.17% compared to the beginning of the period, primarily due to the increase in stock of goods and work in progress[15] - Other current assets increased by 197.88% compared to the beginning of the period, mainly due to the increase in unrecoverable input tax by subsidiaries[15] Expenses - Development expenses increased by 1,562.37% compared to the beginning of the period, mainly due to the purchase of a new drug and related clinical research expenses[15] - Sales expenses increased by 38.92% year-on-year, mainly due to enhanced market investment and promotion efforts for key products[16] - Financial expenses increased by 291.11% year-on-year, primarily due to the accrual of equity premium income and bank loan interest[16] - Net cash flow from operating activities showed a significant decline of 269.65%, resulting in a negative cash flow of CNY 28,744,399.44[7] - Net cash flow from operating activities decreased by 92.17% year-on-year, mainly due to increased cash outflows for raw material purchases and service fees[16] - Net cash flow from investing activities decreased by 550.12% year-on-year, primarily due to increased cash payments for construction projects and new drug development[16] Shareholder Information - The total number of shareholders at the end of the reporting period was 8,029[11] - The largest shareholder, Zhejiang Apac Group Co., Ltd., holds 20.15% of the shares, totaling 108,100,000 shares[11] Corporate Governance - There are no violations regarding external guarantees during the reporting period[29] - There are no non-operating fund occupations by controlling shareholders or related parties during the reporting period[30] - The company did not engage in entrusted financial management during the reporting period[31] - No research, communication, or interview activities were conducted during the reporting period[32] Future Plans and Developments - The company plans to issue convertible bonds with a total fundraising amount not exceeding RMB 965 million, with a term of six years[20] - The company received a GMP certificate for its newly built production line, which will enhance production capacity and quality standards[22] - There were no significant new product developments or market expansion strategies mentioned in the report[14]
亚太药业(002370) - 2018 Q2 - 季度财报
2018-08-28 16:00
Financial Performance - The company's operating revenue for the reporting period was ¥662,249,365.61, representing a 33.88% increase compared to ¥494,646,766.92 in the same period last year[17]. - Net profit attributable to shareholders was ¥131,349,900.19, up 29.27% from ¥101,607,324.81 year-on-year[17]. - The net profit after deducting non-recurring gains and losses was ¥129,680,426.62, reflecting a 34.22% increase from ¥96,620,835.92 in the previous year[17]. - Operating profit reached ¥159,402,838.13, reflecting a growth of 39.52% compared to the previous year[38]. - The total operating revenue for the reporting period reached ¥662,249,365.61, representing a year-on-year increase of 33.88% compared to ¥494,646,766.92 in the same period last year[44]. - Revenue from the pharmaceutical manufacturing sector increased by 66.00% to ¥320,947,355.85, up from ¥193,343,105.17 in the previous year[44]. - Clinical research service revenue surged by 293.10% to ¥157,027,390.83, driven by increased CRO service income from the subsidiary Shanghai New Summit[47]. - The gross profit margin for the pharmaceutical manufacturing sector improved to 55.35%, up from 46.15% in the previous year, reflecting a 9.20% increase[45]. - The company reported a significant increase in high-margin product revenue, driven by a shift to precision marketing and optimized product structure[30]. - The company achieved operating revenue of ¥662,249,365.61, a year-on-year increase of 33.88%[38]. Assets and Liabilities - The company's total assets increased by 17.81% to ¥3,225,849,377.89 from ¥2,738,063,462.43 at the end of the previous year[17]. - The net assets attributable to shareholders rose by 3.26% to ¥2,435,987,679.21 from ¥2,359,015,565.31 at the end of the previous year[17]. - The company's total liabilities rose to ¥778,185,957.25 from ¥368,791,371.59, indicating a significant increase of approximately 110.7%[150]. - Non-current liabilities increased to ¥487,556,706.17 from ¥101,288,541.57, a rise of about 381.5%[150]. - The company's inventory increased by 36.37%, attributed to increased stock of finished goods and work-in-progress[32]. - Cash and cash equivalents at the end of the reporting period totaled ¥822,372,878.91, a decrease of 8.96% from ¥883,426,159.99 at the end of the previous year[49]. Research and Development - The company invested ¥16,652,417.32 in R&D, a slight increase of 1.61% from the previous year[42]. - The company has seen a 1540.95% increase in development expenditures, mainly due to the purchase of a new drug and clinical research expenses[32]. - The company is focusing on the development of innovative drugs and generics, responding to national policies encouraging innovation in the pharmaceutical sector[38]. - The company is focused on enhancing its research and development capabilities to support future growth and market expansion[79]. Risk Factors - The company emphasizes the importance of risk factors including regulatory changes, product quality control, and rising production costs[4]. - The company faces risks from industry regulations and policy changes, which could impact operational costs and market conditions[79]. - Product quality control remains a critical risk, with potential impacts on reputation and operational activities if quality issues arise[79]. - Rising production costs are a concern due to the increasing prices of raw materials and labor, but the company is implementing comprehensive budget management and cost control measures to mitigate these risks[82]. - The company acknowledges the increasing difficulty and duration of drug registration processes, which may pose risks to product upgrades and project investments, and plans to focus on key R&D projects[81]. Shareholder Information - The company reported no cash dividends, stock bonuses, or capital reserve transfers for the period[5]. - The company's major shareholders include Zhejiang Yatai Group Co., Ltd. and Shaoxing Keqiao Yatai Real Estate Co., Ltd.[9]. - Zhejiang Yatai Group holds 26.77% of shares, totaling 143,600,000 common shares, with 94,600,000 shares pledged[134]. - Shaoxing Keqiao Yatai Real Estate Co., Ltd. holds 10.10% of shares, totaling 54,162,000 common shares, with 35,000,000 shares pledged[134]. - Chen Yaogen, the actual controller, holds 5.06% of shares, totaling 27,140,218 common shares, with 25,000,000 shares pledged[134]. Financial Management - The company has not disclosed specific financial metrics or performance indicators in the provided content[12]. - The half-year financial report has not been audited, indicating a need for careful financial oversight[90]. - The company has not engaged in any securities or derivative investments during the reporting period[59][60]. - The company has not made any significant equity investments during the reporting period[55]. - The company has not reported any major changes in the feasibility of the adjusted projects[68]. Environmental Compliance - The company has established wastewater treatment facilities with a design capacity of 365 tons per day, ensuring compliance with the "Comprehensive Discharge Standard for Wastewater" (GB8978-1996) at the tertiary level for wastewater quality indicators[117]. - The company reported an average daily COD discharge of 245 tons, with a maximum allowable discharge of 365 tons per day, and all emissions met relevant standards[116]. - The company has strengthened daily management, ensuring that environmental protection facilities operate normally and comply with pollution control requirements[116]. - The company’s hazardous waste is classified, stored, and disposed of by qualified units to ensure compliance with environmental regulations[117]. Corporate Governance - The company is committed to ensuring the accuracy and completeness of the financial report, with key personnel affirming its integrity[3]. - The company has established a comprehensive quality control system to mitigate risks associated with product safety and compliance[79]. - The company plans to strengthen internal controls and improve external oversight to enhance the management capabilities of its subsidiaries, addressing potential operational risks[80]. - The company has no media scrutiny or regulatory penalties during the reporting period[94][95].
亚太药业(002370) - 2018 Q1 - 季度财报
2018-04-20 16:00
Financial Performance - The company's revenue for Q1 2018 was CNY 319,164,772.95, representing a 29.48% increase compared to CNY 246,492,170.82 in the same period last year[7]. - Net profit attributable to shareholders was CNY 65,492,888.74, up 40.05% from CNY 46,764,741.57 year-on-year[7]. - The net profit after deducting non-recurring gains and losses was CNY 64,972,171.00, reflecting a 38.85% increase from CNY 46,793,986.08 in the previous year[7]. - The basic earnings per share increased to CNY 0.12, a rise of 33.33% from CNY 0.09 in the same quarter last year[7]. - The net profit attributable to shareholders for the first half of 2018 is expected to increase by 25.00% to 40.00%, ranging from CNY 12,700.91 million to CNY 14,225.02 million[18]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,970,623,123.08, an increase of 8.49% from CNY 2,738,063,462.43 at the end of the previous year[7]. - The net assets attributable to shareholders reached CNY 2,424,430,556.65, which is a 2.77% increase from CNY 2,359,015,565.31 at the end of the last year[7]. - Short-term borrowings decreased by 62.50% compared to the beginning of the period, mainly due to a reduction in bank borrowings by subsidiaries[14]. Cash Flow - The net cash flow from operating activities was negative at CNY -43,517,271.69, a significant decrease of 170.69% compared to CNY 61,564,589.85 in the same period last year[7]. - Operating cash flow decreased by 170.69% year-on-year, mainly due to increased cash payments for goods and services[15]. Shareholder Information - The company reported a total of 7,521 common shareholders at the end of the reporting period[10]. - Zhejiang Apac Group Co., Ltd. held the largest share with 26.77%, amounting to 143,600,000 shares[10]. Expenditures and Investments - Prepayments increased by 97.77% compared to the beginning of the period, mainly due to increased prepayment for technical services by subsidiaries[14]. - Other current assets increased by 48.00% compared to the beginning of the period, primarily due to an increase in unrecoverable input tax by subsidiaries[14]. - Development expenditures increased by 1608.27% compared to the beginning of the period, mainly due to the purchase of a new drug, recombinant human keratinocyte growth factor-2[14]. - Sales expenses increased by 143.36% year-on-year, primarily due to enhanced market investment and promotion of key products[15]. Return on Investment - The weighted average return on net assets was 2.74%, up from 2.12% in the previous year[7].
亚太药业(002370) - 2017 Q4 - 年度财报
2018-04-20 16:00
Financial Performance - The company's operating revenue for 2017 was ¥1,082,951,050.52, representing a 25.51% increase compared to ¥862,874,547.46 in 2016[6]. - The net profit attributable to shareholders for 2017 was ¥202,152,119.51, a 61.35% increase from ¥125,290,559.06 in 2016[6]. - The net profit after deducting non-recurring gains and losses was ¥193,541,230.47, up 64.42% from ¥117,710,119.83 in 2016[6]. - The net cash flow from operating activities reached ¥127,593,606.87, a significant increase of 435.35% compared to -¥38,047,671.82 in 2016[6]. - The basic earnings per share for 2017 was ¥0.38, reflecting a 35.71% increase from ¥0.28 in 2016[6]. - Operating profit reached ¥237,157,418.52, reflecting a growth of 75.13% compared to the previous year[53]. - The company reported a 34.48% increase in service revenue, amounting to ¥620,375,704.75, compared to the previous year[60]. - Clinical research services saw a significant growth of 134.89%, reaching ¥186,558,697.50[61]. - The total revenue from domestic operations was ¥1.08 billion, with a year-on-year growth of 25.37%[63]. - The company reported a net profit of RMB 202,152,119.51 for 2017, with a cash dividend payout ratio of 100%[130]. Investment and Capital Structure - The company raised a total of RMB 1,324,135,369.08 through a non-public offering of 64,247,228 shares at RMB 20.61 per share, with net proceeds after fees amounting to RMB 1,297,135,369.08[99]. - The company invested RMB 12,000.00 million to increase the registered capital of its wholly-owned subsidiary, Shaoxing Yatai Pharmaceutical Co., Ltd., from RMB 40 million to RMB 160 million[92]. - The total investment during the reporting period was 701,196,476.28 yuan, a decrease of 27.01% compared to the same period last year[86]. - The company has committed to invest a total of RMB 90,000 million in the acquisition of 100% equity of Shanghai New Gaofeng, with an actual investment of RMB 87,750 million, achieving a progress rate of 97.50%[103]. - The company completed a capital increase of RMB 4 billion, with Hubei Province Science and Technology Investment Group holding 49% and the company holding 51%[170]. Research and Development - The company has a strong R&D capability supported by a provincial-level enterprise technology center and collaborations with renowned research institutions and universities[48]. - The company increased its R&D investment, focusing on enhancing independent innovation capabilities and expediting clinical research[53]. - The company’s R&D expenditure for the reporting period was ¥48,551,105.07, accounting for 4.48% of total revenue[73]. - R&D investment rose by 79.84% compared to the previous year, from ¥26,996,714.47 to ¥48,551,105.07[75]. - The company aims to enhance its research capabilities in the field of pharmaceuticals and medical technology[87]. Market and Industry Trends - The pharmaceutical industry in China is experiencing stable growth due to increased disposable income, improved healthcare coverage, and an aging population[32]. - Future growth in the pharmaceutical sector is anticipated due to demographic changes, increased healthcare spending, and a shift towards innovative technologies and business models[39]. - The CRO industry in China has grown from 14 billion to 46.2 billion RMB from 2011 to 2016, with a compound annual growth rate of 27%[44]. - The CRO industry in China is expected to maintain a growth rate of over 20% in the coming years, with a projected market size of 97.5 billion RMB by 2020[44]. Regulatory Environment - The company emphasizes the importance of risk factors including regulatory changes, product quality control, and rising production costs[4]. - In 2017, over 300 national-level policy documents related to the pharmaceutical industry were issued, indicating a significant regulatory shift aimed at improving drug procurement and market dynamics[35]. - The "Two Invoice System" policy was introduced to streamline drug procurement processes, reduce prices, and enhance drug quality and safety[35]. - The "13th Five-Year" National Drug Safety Plan was implemented to improve drug quality and safety governance by 2020, aiming for higher public satisfaction and regulatory standards[36]. - The introduction of priority review and approval for innovative drugs and generics is expected to accelerate industry structure adjustment and technological innovation[38]. Operational Efficiency - The company has optimized its product structure and integrated industrial resources to enhance operational capabilities in response to the evolving regulatory environment[52]. - The company has established a complete pharmaceutical business value chain, including a wide range of products such as anti-infectives, antiviral drugs, and biochemical diagnostic reagents, which helps mitigate operational risks[48]. - The company has developed a comprehensive marketing system that covers commercial channels, retail pharmacies, and clinical hospitals, facilitating effective product promotion[48]. - The company aims to enhance its marketing capabilities and optimize its product structure to increase the market share of high-margin products[54]. Risk Management - The company acknowledges the challenges in drug development and registration due to increasing regulatory complexity and aims to manage these risks through careful project selection and investment[119]. - The company faces risks from regulatory changes in the pharmaceutical industry, which could impact operational costs and require timely strategic adjustments[116]. - Product quality control remains a critical focus, with ongoing efforts to enhance quality management and production processes to mitigate risks[116]. - The company emphasizes the importance of maintaining a robust internal control system to manage the increasing complexity of its subsidiary operations[118]. Corporate Governance - The company has established a comprehensive corporate governance structure and internal control system to protect the rights of shareholders and creditors[172]. - The company has implemented strict compliance measures to ensure adherence to these commitments by its management and shareholders[137]. - The company is committed to transparency and accountability in its governance practices to protect shareholder interests[137]. - The company has outlined a clear framework for penalties and compensation related to breaches of its commitments[136]. Shareholder Relations - The company distributed cash dividends of RMB 53,649,445.60 for the fiscal year 2017, which is 26.54% of the net profit attributable to shareholders[130]. - The total share capital increased to 536,494,456 shares after a capital reserve conversion of 268,247,228 shares in September 2017[125]. - The company has maintained a consistent cash dividend policy, distributing RMB 1.00 per 10 shares for the past three years[127]. - The company reported a commitment from its major shareholders to avoid engaging in any business activities that compete with the company or its subsidiaries[136].
亚太药业(002370) - 2017 Q3 - 季度财报
2017-10-23 16:00
浙江亚太药业股份有限公司 2017 年第三季度报告正文 证券代码:002370 证券简称:亚太药业 公告编号:2017-065 浙江亚太药业股份有限公司 2017 年第三季度报告正文 1 浙江亚太药业股份有限公司 2017 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人陈尧根、主管会计工作负责人何珍及会计机构负责人(会计主管 人员)何珍声明:保证季度报告中财务报表的真实、准确、完整。 2 浙江亚太药业股份有限公司 2017 年第三季度报告正文 第二节 公司基本情况 非经常性损益项目和金额 √ 适用 □ 不适用 单位:元 | 项目 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益(包括已计提资产减值准备的冲销部分) | 536,198.72 | | | 计入当期损益的政府补助(与企业业务密切相关,按照国家统 一标准定额或定量享受的政府补助除外) | 5,812 ...